$299.29
4.291.45%
Last update: Oct 9, 12:06 PM
$295.00
N/A
Ligand Pharmaceuticals Inc
LGNDNASDAQ
Ligand Pharmaceuticals (LGND) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Ligand Pharmaceuticals (LGND) last issued guidance on August 6, 2026 for fiscal year 2026. The company guided earnings per share in the range of $9 - $9.5, compared to a consensus EPS estimate of $8.13. Ligand Pharmaceuticals also guided revenue in the range of $270M - $310M for the period.
Compared to prior guidance, Ligand Pharmaceuticals raised its EPS outlook from a previous range of $8.5 - $9.5. On the revenue side, the company maintained its revenue forecast from a prior range of $270M - $310M.
Ligand Pharmaceuticals has issued 26 guidance updates between November 7, 2022 and August 6, 2026. During this period, the company raised its outlook 14 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.84 | $1.64 | $1.15 | $1.57 |
| Actual | $2.37 | $1.63 | $2.02 | $3.09 |
| Surprise | +28.8% | -0.61% | +75.6% | +96.8% |
| Revenue | ||||
| Estimate | $63.5M | $59.1M | $56.6M | $58.5M |
| Actual | $63.7M | $51.7M | $59.7M | $115.5M |
| Surprise | +0.23% | -12.4% | +5.38% | +97.2% |
| Metric | Q3 '26E | Q4 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $2.13 | $2.82 |
| Revenue | ||
| Consensus | $77.8M | $96.7M |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $2.37 | $1.84 | 28.8 % |
| Q1 | May 7, 2026 | $1.63 | $1.64 | -0.61 % |
| Q4 | Feb 26, 2026 | $2.02 | $1.15 | 75.6 % |
| Q3 | Nov 6, 2025 | $3.09 | $1.57 | 96.8 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $63.69M | $63.54M | 0.23 % |
| Q1 | May 7, 2026 | $51.72M | $59.06M | -12.4 % |
| Q4 | Feb 26, 2026 | $59.67M | $56.62M | 5.38 % |
| Q3 | Nov 6, 2025 | $115.46M | $58.54M | 97.2 % |
